66 related articles for article (PubMed ID: 17604264)
41. CYP2C9 genotype and association with bone mineral density: a pilot study.
Brunner-Ziegler S; Giurgea GA; Sunder-Plassmann R; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
Gene; 2013 Sep; 526(2):295-8. PubMed ID: 23732294
[TBL] [Abstract][Full Text] [Related]
42. Polymorphisms of OPG and their relation to the mineral density of bones in pre- and postmenopausal women.
Boroń D; Kotrych D; Bartkowiak-Wieczorek J; Uzar I; Bogacz A; Kamiński A
Int Immunopharmacol; 2015 Sep; 28(1):477-86. PubMed ID: 26202809
[TBL] [Abstract][Full Text] [Related]
43. Analysis of three functional polymorphisms in relation to osteoporosis phenotypes: replication in a Spanish cohort.
Agueda L; Urreizti R; Bustamante M; Jurado S; Garcia-Giralt N; Díez-Pérez A; Nogués X; Mellibovsky L; Grinberg D; Balcells S
Calcif Tissue Int; 2010 Jul; 87(1):14-24. PubMed ID: 20390408
[TBL] [Abstract][Full Text] [Related]
44. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
45. Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women.
Ogata N; Matsumura Y; Shiraki M; Kawano K; Koshizuka Y; Hosoi T; Nakamura K; Kuro-O M; Kawaguchi H
Bone; 2002 Jul; 31(1):37-42. PubMed ID: 12110410
[TBL] [Abstract][Full Text] [Related]
46. A prospective study of dehydroepiandrosterone sulfate (DHEAS) and bone mineral density in older men and women.
Barrett-Connor E; Kritz-Silverstein D; Edelstein SL
Am J Epidemiol; 1993 Jan; 137(2):201-6. PubMed ID: 8452124
[TBL] [Abstract][Full Text] [Related]
47. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1.
Rodriguez-Antona C; Axelson M; Otter C; Rane A; Ingelman-Sundberg M
J Biol Chem; 2005 Aug; 280(31):28324-31. PubMed ID: 15937338
[TBL] [Abstract][Full Text] [Related]
48. Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
Neunzig I; Drăgan CA; Widjaja M; Schwaninger AE; Peters FT; Maurer HH; Bureik M
Biochim Biophys Acta; 2011 Jan; 1814(1):161-7. PubMed ID: 20637317
[TBL] [Abstract][Full Text] [Related]
49. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine.
Burk O; Tegude H; Koch I; Hustert E; Wolbold R; Glaeser H; Klein K; Fromm MF; Nuessler AK; Neuhaus P; Zanger UM; Eichelbaum M; Wojnowski L
J Biol Chem; 2002 Jul; 277(27):24280-8. PubMed ID: 11940601
[TBL] [Abstract][Full Text] [Related]
50. CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.
Sood D; Johnson N; Jain P; Siskos AP; Bennett M; Gilham C; Busana MC; Peto J; Dos-Santos-Silva I; Keun HC; Fletcher O
Br J Cancer; 2017 Jan; 116(3):382-388. PubMed ID: 28072767
[TBL] [Abstract][Full Text] [Related]
51. Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms.
Zhai G; Teumer A; Stolk L; Perry JR; Vandenput L; Coviello AD; Koster A; Bell JT; Bhasin S; Eriksson J; Eriksson A; Ernst F; Ferrucci L; Frayling TM; Glass D; Grundberg E; Haring R; Hedman AK; Hofman A; Kiel DP; Kroemer HK; Liu Y; Lunetta KL; Maggio M; Lorentzon M; Mangino M; Melzer D; Miljkovic I; ; Nica A; Penninx BW; Vasan RS; Rivadeneira F; Small KS; Soranzo N; Uitterlinden AG; Völzke H; Wilson SG; Xi L; Zhuang WV; Harris TB; Murabito JM; Ohlsson C; Murray A; de Jong FH; Spector TD; Wallaschofski H
PLoS Genet; 2011 Apr; 7(4):e1002025. PubMed ID: 21533175
[TBL] [Abstract][Full Text] [Related]
52. Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population.
Lee SS; Jung HJ; Park JS; Cha IJ; Cho DY; Shin JG
Mol Biol Rep; 2010 Jan; 37(1):213-7. PubMed ID: 19585271
[TBL] [Abstract][Full Text] [Related]
53. CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women.
Bácsi K; Kósa JP; Borgulya G; Balla B; Lazáry A; Nagy Z; Horváth C; Speer G; Lakatos P
Calcif Tissue Int; 2007 Mar; 80(3):154-9. PubMed ID: 17334880
[TBL] [Abstract][Full Text] [Related]
54. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels.
Smit P; van Schaik RH; van der Werf M; van den Beld AW; Koper JW; Lindemans J; Pols HA; Brinkmann AO; de Jong FH; Lamberts SW
J Clin Endocrinol Metab; 2005 Sep; 90(9):5313-6. PubMed ID: 15985487
[TBL] [Abstract][Full Text] [Related]
55. Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.
Goodarzi MO; Xu N; Azziz R
J Clin Endocrinol Metab; 2008 Jul; 93(7):2909-12. PubMed ID: 18445661
[TBL] [Abstract][Full Text] [Related]
56. Dehydroepiandrosterone sulphate in the diagnosis of osteoporosis.
Miklós S
Acta Biomed Ateneo Parmense; 1995; 66(3-4):139-46. PubMed ID: 8578930
[TBL] [Abstract][Full Text] [Related]
57. Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey.
Yilmaz MB; Pazarbasi A; Guzel AI; Kocaturk-Sel S; Kasap H; Kasap M; Urunsak IF; Basaran S; Alptekin D; Demirhan O
Genet Mol Res; 2011 Sep; 10(3):1999-2008. PubMed ID: 21948762
[TBL] [Abstract][Full Text] [Related]
58. [Impact of CYP3A7*1C polymorphism on bone mineral content in postmenopausal women].
Bácsi K; Kósa J; Lazáry A; Balla B; Horváth H; Takács I; Nagy Z; Speer G; Lakatos P
Orv Hetil; 2007 Jul; 148(27):1273-80. PubMed ID: 17604264
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
